ES2196806T3 - Derivados de fenilurea y de feniltiourea. - Google Patents

Derivados de fenilurea y de feniltiourea.

Info

Publication number
ES2196806T3
ES2196806T3 ES99923540T ES99923540T ES2196806T3 ES 2196806 T3 ES2196806 T3 ES 2196806T3 ES 99923540 T ES99923540 T ES 99923540T ES 99923540 T ES99923540 T ES 99923540T ES 2196806 T3 ES2196806 T3 ES 2196806T3
Authority
ES
Spain
Prior art keywords
alkyl
alkoxy
sulfur
phenyl
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99923540T
Other languages
English (en)
Inventor
Amanda Johns
Roderick Alan Porter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9809988.0A external-priority patent/GB9809988D0/en
Priority claimed from GBGB9809972.4A external-priority patent/GB9809972D0/en
Priority claimed from GBGB9903268.2A external-priority patent/GB9903268D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of ES2196806T3 publication Critical patent/ES2196806T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. Un compuesto de fórmula (I): en la cual: uno de X e Y es N, y el otro es CH; Z representa oxígeno o azufre; R1 representa alquilo(C1-6), alquenilo(C2-6) o alcoxi(C1-6); halógeno, R7CO- ó NR8R9CO-; R2, R3, R4, R5 y R6 representan independientemente alquilo(C1-6), alquenilo(C2-6), alcoxi(C1-6) o tioalquilo(C1-6); hidrógeno, halógeno, nitro, ciano, fenoxi, naftiloxi, fenilalcoxi(C1-6), naftilalcoxi(C1-6), fenilalquilo(C1-6), naftilalquilo(C1-6), R7CO-, R7SO2NH-, R7CON(R10)-, NR8R9-, NR8R9CO-, -COOR8, un anillo monocíclico o bicíclico de 5 a 10 miembros, que puede estar insaturado o saturado, que contiene 1 a 3 heteroátomos seleccionados entre oxígeno, nitrógeno o azufre, o un alquilo(C1-6) sustituido con un anillo monocíclico o bicíclico de 5 a 10 miembros, que puede estar insaturado o saturado, que contiene 1 a 3 heteroátomos seleccionados entre oxígeno, nitrógeno o azufre; o un par adyacente de R2, R3, R4, R5 y R6 junto con los átomos de carbono a los cuales están unidos, forman un anillocarbocíclico o heterocíclico aromático o no aromático de 5 a 7 miembros, en el que el anillo heterocíclico contiene 1, 2 ó o 3 heteroátomos seleccionados entre oxígeno, nitrógeno y azufre, y en el que el anillo carbocíclico o heterocíclico puede estar insustituido o sustituido en el carbono o nitrógeno con uno o más sustituyentes seleccionados entre =O, alquilo(C1-4), fenilalquilo(C1-4), naftilalquilo(C1-4), fenilo, naftilo, alcoxi(C1-4), alcoxi(C1-4)alquil(C1-4)hidroxi, hidroxialquilo(C1-4), RaCO2-, RaCO2alquilo(C1-4), ciano, cianoalquilo(C1-4), RaRbN y RaRbNalquilo(C1-4); en el cual, Ra y Rb son independientemente seleccionados entre hidrógeno y alquilo(C1-4); R7 es alquilo(C1-6), fenilo o naftilo; R8 y R9 representan independientemente hidrógeno, alquilo (C1-6), fenilo, naftilo, fenilalquilo(C1-6) o naftilalquilo(C1-6); R10 es hidrógeno o alquilo(C1-6); y n es 0, 1, 2 ó 3; en donde alquilo puede ser una cadena lineal, ramificada o cíclica; o una sal farmacéuticamente aceptable del mismo.
ES99923540T 1998-05-08 1999-05-04 Derivados de fenilurea y de feniltiourea. Expired - Lifetime ES2196806T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9809988.0A GB9809988D0 (en) 1998-05-08 1998-05-08 Compounds
GBGB9809972.4A GB9809972D0 (en) 1998-05-08 1998-05-08 Compounds
GBGB9903268.2A GB9903268D0 (en) 1999-02-12 1999-02-12 Compounds

Publications (1)

Publication Number Publication Date
ES2196806T3 true ES2196806T3 (es) 2003-12-16

Family

ID=27269308

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99923540T Expired - Lifetime ES2196806T3 (es) 1998-05-08 1999-05-04 Derivados de fenilurea y de feniltiourea.

Country Status (8)

Country Link
US (1) US6372757B1 (es)
EP (1) EP1075478B1 (es)
JP (1) JP4633925B2 (es)
AU (1) AU4037799A (es)
CA (1) CA2331735A1 (es)
DE (1) DE69906960T2 (es)
ES (1) ES2196806T3 (es)
WO (1) WO1999058533A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093820A (en) 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
ATE241345T1 (de) * 1999-02-12 2003-06-15 Smithkline Beecham Plc Neue verwendung von orexinrezeptorantagonisten
WO2000047576A1 (en) * 1999-02-12 2000-08-17 Smithkline Beecham Plc Cinnamide derivatives as orexin-1 receptors antagonists
DE60015927T2 (de) * 1999-02-12 2005-04-07 Smithkline Beecham P.L.C., Brentford Phenylharnstoff und phenylthioharnstoffderivate
BRPI0109200B8 (pt) 2000-03-14 2021-05-25 Actelion Pharmaceuticals Ltd compostos e composições farmacêuticas
EP1288202A4 (en) * 2000-05-11 2003-07-02 Banyu Pharma Co Ltd N-ACYLTETRAHYDROISOQUINOLINE DERIVATIVES
PT1289955E (pt) 2000-06-16 2005-08-31 Smithkline Beecham Plc Piperidinas para utilizacao como antagonistas dos receptores da orexina
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
IL158463A0 (en) 2001-05-05 2004-05-12 Smithkline Beecham Plc N-aroyl cyclic amines
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0130335D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
AU2003246657A1 (en) 2002-07-09 2004-01-23 Actelion Pharmaceuticals Ltd. 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives
JP4528125B2 (ja) 2002-10-11 2010-08-18 アクテリオン ファーマシューティカルズ リミテッド スルホニルアミノ−酢酸誘導体
AR042444A1 (es) * 2002-12-11 2005-06-22 Taro Pharmaceuticals Ireland L Metodo para el tratamiento de desordenes del movimiento mediante la utilizacion de acido barbiturico
CA2520839A1 (en) 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Quinoxalinone-3- one derivatives as orexin receptor antagonists
US20050032794A1 (en) * 2003-08-05 2005-02-10 Padia Janak K. Diamine derivatives of quinone and uses thereof
HUP0304101A3 (en) * 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
BRPI0508263B8 (pt) 2004-03-01 2021-05-25 Idorsia Pharmaceuticals Ltd derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
CA2572797A1 (en) * 2004-07-02 2006-01-12 Daniella Gutman A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
US20060178307A1 (en) * 2005-01-26 2006-08-10 The Regents Of The University Of California Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor
US7501395B2 (en) 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
EP2049110B1 (en) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
US20080132529A1 (en) * 2006-11-14 2008-06-05 Avraham Yacobi Method of improving bioavailability for non-sedating barbiturates
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CL2008001003A1 (es) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
US8263586B2 (en) 2007-05-18 2012-09-11 Merck Sharp & Dohme Corp. OXO bridged diazepan orexin receptor antagonists
US8242121B2 (en) 2007-05-23 2012-08-14 Merck Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
WO2009133522A1 (en) * 2008-04-30 2009-11-05 Actelion Pharmaceuticals Ltd Piperidine and pyrrolidine compounds
CA2745420A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
EA201171293A1 (ru) 2009-04-24 2012-05-30 Глэксо Груп Лимитед 3-азабицикло[4.1.0]гептаны, применяемые в качестве антагонистов орексина
EP2470525A1 (en) 2009-08-24 2012-07-04 Glaxo Group Limited Piperidine derivatives used as orexin antagonists
JP2013502447A (ja) 2009-08-24 2013-01-24 グラクソ グループ リミテッド 睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体
WO2011031745A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
EP2332939A1 (en) 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
WO2013119639A1 (en) 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
JP6663909B2 (ja) 2014-08-13 2020-03-13 エオラス セラピューティクス， インコーポレイテッド オレキシンレセプターモジュレーターとしてのジフルオロピロリジン
EP3414241B1 (en) 2016-02-12 2022-05-04 Astrazeneca AB Halo-substituted piperidines as orexin receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0222839A4 (en) 1985-05-17 1988-11-09 Univ Australian ANTI-MALARIA COMPOUNDS.
JPH05213884A (ja) 1991-06-14 1993-08-24 Upjohn Co:The 新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
EP0842933B1 (en) 1995-05-31 2004-08-04 Sumitomo Pharmaceuticals Company, Limited Novel naphthyridine derivatives
US5972936A (en) 1996-05-20 1999-10-26 Darwin Discover Limited Benzofuran carboxamides and their therapeutic use
AR016817A1 (es) * 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento

Also Published As

Publication number Publication date
DE69906960T2 (de) 2004-01-29
AU4037799A (en) 1999-11-29
US6372757B1 (en) 2002-04-16
CA2331735A1 (en) 1999-11-18
DE69906960D1 (en) 2003-05-22
JP2003522101A (ja) 2003-07-22
EP1075478A1 (en) 2001-02-14
EP1075478B1 (en) 2003-04-16
WO1999058533A1 (en) 1999-11-18
JP4633925B2 (ja) 2011-02-16

Similar Documents

Publication Publication Date Title
ES2196806T3 (es) Derivados de fenilurea y de feniltiourea.
AR009212A1 (es) Un derivado de 3-piperidil-4-oxoquinazolina; una composicion farmaceutica, un inhibidor de la proteina de transferencia de los trigliceridos microsomal(mtp) y un agente terapeutico o preventivo para la hiperlipemia o la arteriosclerosis que lo contienen
ES2002254A4 (es) Nuevos 5-alcoxi-2,4-diamino-alquilbenzenos asi como tintes para el cabello con 5-alcoxi-2,4-diamino-alquil-benzenos.
ES2220529T3 (es) Dibenzopiranos utiles como antagonistas del receptor de los glucocorticoides, en el tratamiento de la diabetes.
ECSP941146A (es) Derivados de benzofurano
AR241014A2 (es) "procedimiento para la preparacion de feniletanolami-notetralinas de actividad lipolitica"
CO5560610A2 (es) Derivados de yodobenzopiran-4-ona que tienen actividad fungicida
CO5021127A1 (es) Nuevas dihidropirimidas
AR034282A1 (es) Derivados de difenilazetidinona, medicamentos que contienen estos compuestos, procedimiento para su preparacion, y su utilizacion para la preparacion de medicamentos
GT199900119A (es) Jarabe antihistaminico estabilizado.
ES2166270B1 (es) Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
FI862757A (fi) Pyridonkarbonsyraderivat och foerfarande foer framstaellning av dessa.
ES2142773B1 (es) Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida.
CO4970752A1 (es) Nuevos derivados de isatin y composiciones farmaceuticas conteniendo tales isatines
ES2037257T3 (es) Procedimiento de obtencion de los derivados de n-aminobutil y n-fenil arilamidas.
SE8505887L (sv) Indoler
AR012157A1 (es) Derivados de piridina, composiciones farmaceuticas que los contienen y procedimiento para la preparacion de dichos derivados.
AR040140A1 (es) Derivados de esteres de camptotecina en la posicion 20
CO4970779A1 (es) Derivados del acido aminoetilfenoxiacetico y agentes para reducir el dolor y promover la eliminacion de calculos en urolitiasis
AR040139A1 (es) Camptotecinas con un anillo lactona modificado
ES2037011T3 (es) Procedimiento para la preparacion de nuevos derivados de benzofuran-2-il-imidazol.
ES2183434T3 (es) Derivados de cromano sustituidos con carboxilo utiles como agonistas de adrenoreceptores.
CO4940478A1 (es) Derivados de 1-(2-acilimidazol-1-ilalquil) quinuclidino
CO4920222A1 (es) Inhibidores cetona con c-terminal de las metaloproteinas de matriz y de la secrecion del fnt[alfa]
ES2179548T3 (es) Nuevos derivados de la acronicina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.